UNSPSC 51362402: Niaprazine

This classification denotes a sedative and hypnotic with the molecular formula C20H25FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2H3YN6E3L, chemically known as 3-pyridinecarboxamide, n-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)- (9ci) but generally known as niaprazine, which bears US NIH Compound Identifier 71919. European Medicines Agency schedules Niaprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09218MIG.

UNSPSC 51362402 Niaprazine is a Commodity code that in recent state and local procurement records designates pharmaceutical products, though the actual solicitations tied to this code span naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products rather than niaprazine specifically. State and local buyers using this code procure pharmaceutical inventory for community health programs, pharmacy benefit systems, and multi-jurisdiction cooperative purchasing alliances. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon). The work spans direct pharmaceutical procurement, drug supply chain management, and wholesale distribution coordination through authorized pharmacy distribution channels.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage planning for expanded direct pharmaceutical contracting outside traditional pharmacy benefit manager relationships. The Minnesota Department of Administration's Office of State Procurement, acting through MMCAP, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026, and awarded vendors effective July 1, 2026. Vendors responding to MMCAP must maintain relationships with specified wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, carry commercial general liability insurance of $5,000,000 per occurrence, and accept a 3 percent administrative fee on all contract purchases.